Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019

BACKGROUND: The B-cell-depleting anti-CD20 antibody rituximab (RTX) is often used as an adjuvant drug for the treatment of refractory cases of mucous membrane pemphigoid (MMP). OBJECTIVE: This study aims to determine the therapeutic effectiveness and the safety profile of RTX in MMP. METHODS: The me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamberger, Florian, König, Inke R., Gola, Damian, Zillikens, Detlef, Sadik, Christian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153668/
https://www.ncbi.nlm.nih.gov/pubmed/37143653
http://dx.doi.org/10.3389/fimmu.2023.1180150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153668/
https://www.ncbi.nlm.nih.gov/pubmed/37143653
http://dx.doi.org/10.3389/fimmu.2023.1180150

Ejemplares similares